PL4294395T3 - Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077 - Google Patents

Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077

Info

Publication number
PL4294395T3
PL4294395T3 PL22713478.0T PL22713478T PL4294395T3 PL 4294395 T3 PL4294395 T3 PL 4294395T3 PL 22713478 T PL22713478 T PL 22713478T PL 4294395 T3 PL4294395 T3 PL 4294395T3
Authority
PL
Poland
Prior art keywords
gdc
treatment
breast cancer
combination therapies
therapies
Prior art date
Application number
PL22713478.0T
Other languages
English (en)
Inventor
Ciara METCALFE
Xiaojing Wang
Wei Zhou
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80953424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4294395(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL4294395T3 publication Critical patent/PL4294395T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL22713478.0T 2021-02-16 2022-02-14 Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077 PL4294395T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149944P 2021-02-16 2021-02-16
PCT/US2022/016270 WO2022177844A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Publications (1)

Publication Number Publication Date
PL4294395T3 true PL4294395T3 (pl) 2025-06-23

Family

ID=80953424

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22713478.0T PL4294395T3 (pl) 2021-02-16 2022-02-14 Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077

Country Status (8)

Country Link
US (1) US20230381155A1 (pl)
EP (1) EP4294395B1 (pl)
JP (1) JP7904849B2 (pl)
CN (1) CN117377472A (pl)
ES (1) ES3030540T3 (pl)
PL (1) PL4294395T3 (pl)
TW (1) TWI808648B (pl)
WO (1) WO2022177844A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538147A (ja) * 2022-11-02 2025-11-26 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.

Also Published As

Publication number Publication date
JP2024506385A (ja) 2024-02-13
WO2022177844A1 (en) 2022-08-25
EP4294395A1 (en) 2023-12-27
CN117377472A (zh) 2024-01-09
JP7904849B2 (ja) 2026-08-13
ES3030540T3 (en) 2025-06-30
EP4294395C0 (en) 2025-03-26
TWI808648B (zh) 2023-07-11
US20230381155A1 (en) 2023-11-30
EP4294395B1 (en) 2025-03-26
TW202237100A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
IL280707B2 (en) Diagnostic and therapeutic methods for treating breast cancer
HUE073220T2 (hu) KAT6 inhibitor és kombinációk mellrák kezelésére
IL281256A (en) Combined treatment for the treatment of triple-negative breast cancer
IL292197A (en) Leukemia treatment based on anti-cd47 and anti-cd20
IL308766A (en) Compositions and methods for treating prostate cancer
IL279277A (en) In vivo controlled combination therapy for treatment of cancer
LT4340842T (lt) Sotorasibas, skirtas naudoti vėžio gydymui
IL308992A (en) Cancer treatment in patients with soluble FR-alpha
IL279591A (en) Cancer treatment methods using combination therapy
GB202107994D0 (en) Treatment of cancer
IL288178A (en) Combined gmci and ddri treatment for cancer
EP4157246B8 (en) Therapeutic combination for the treatment of breast cancer
IL315250A (en) Combination therapies including GDC-6036 and GDC-0077 for the treatment of cancer
IL275913A (en) Methods and combined treatment for cancer treatment
IL326327A (en) Treatment of prostate cancer
IL314687A (en) Cancer treatment
IL270306A (en) Prevention and treatment of pre-myeloid and myeloid malignancies
IL312899A (en) Combined treatment for cancer
IL300106A (en) Combination therapy for cancer treatment
GB202018062D0 (en) Treatment of cancer
GB202008037D0 (en) Treatment of cancer
GB202311976D0 (en) Treatment of cancer
GB202218181D0 (en) Treatment of cancer
HK40085109A (en) Combination therapy for treatment of cancer and cancer metastasis
GB202201803D0 (en) Treatment of Cancer